Status: Recruiting
The Prospective, Double-blind, Multicenter, Placebo-controlled, Randomized, Comparative Clinical Trial
The main objective of the study is to evaluate the efficacy and safety of Neovasculgen® in a course dose of 2.4 mg in combination with standard drug therapy in patients with unilateral neuroischemic form of diabetic foot syndrome.
Participants needed: 144
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: JSC NextGenUpdated: Feb 5, 2026Locations: 1
Eligibility criteria
Male and female patients aged 18 years and above inclusive (at the time of study... [+9]
Age under 18. [+22]